Exploring the use of tyrosine kinase inhibitors (TKIs) in the management of HER2positive metastatic breast cancer post trastuzumab emtansine (TDM1) therapy failure: Insights from a real-world study

被引：0
|
作者：
Yin, Yongmei
Sun, Chunxiao
Hua, Yijia
Jin, Nan
Li, Wei
Huang, Xiang
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-04-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-04-06
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
    Li, Feng
    Xu, Fengrui
    Li, Jianbin
    Wang, Tao
    Bian, Li
    Zhang, Shaohua
    Jiang, Zefei
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (02)
  • [12] IMPACT OF ADJUVANT TRASTUZUMAB EMTANSINE (TDM1) ON THE INCIDENCE OF HER2-POSITIVE METASTATIC BREAST CANCER AND ITS ASSOCIATED SAVINGS FOR THE SPANISH NATIONAL HEALTHCARE SYSTEM
    Martin, M.
    Albanell, J.
    Moreno, E.
    Costa-Samarra, J.
    Arroyo, I
    Colomer, R.
    VALUE IN HEALTH, 2020, 23 : S435 - S436
  • [13] 64Cu-DOTA-trastuzumab PET/CT to predict response to ado-trastuzumab emtansine (TDM1) in HER2-positive metastatic breast cancer.
    Mortimer, Joanne E.
    Bading, James R.
    Frankel, Paul Henry
    Gidwaney, Rita
    Park, John
    Tumyan, Lusine
    Parayno, Maria
    Poku, Kofi
    Colcher, David
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [14] Evaluating the risk of cardiotoxicity associated with concurrent trastuzumab emtansine (TDM1) and radiation therapy in patients with early-stage HER2 positive breast cancer
    Farooq, Faheem
    Cason, Dillon
    Ohri, Nisha
    Kumar, Shicha
    Grann, Allison
    Litvak, Anna
    Ganesan, Shridar
    Haffty, Bruce G.
    Toppmeyer, Deborah
    Omene, Coral
    George, Mridula A.
    CANCER RESEARCH, 2023, 83 (05)
  • [15] Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer
    Mougalian, S. S.
    Copher, R.
    McAllister, L.
    Radtchenko, J.
    Wang, E. C.
    Broscious, M.
    Yu, H-T
    Kish, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [16] Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study
    Cil, Ibrahim
    Kucukarda, Ahmet
    Atci, Muhammed Mustafa
    Secmeler, Saban
    Paksoy, Nail
    Ferhatoglu, Ferhat
    Ak, Naziye
    Ayhan, Murat
    Ozyukseler, Deniz Tataroglu
    Onder, Arif Hakan
    Avci, Okan
    Oyman, Abdilkerim
    Okten, Ilker Nihat
    Gulturk, Ilkay
    Akagunduz, Baran
    Basoglu, Tugba
    Cakir, Emre
    Hacibekiroglu, Ilhan
    Ozcelik, Melike
    Aydiner, Adnan
    TUMORI JOURNAL, 2022, 108 (01): : 19 - 25
  • [17] Real-world study of the treatments following trastuzumab-emtansine for HER2-positive metastatic breast cancer: A multicentral cohort study (WJOG12519B).
    Kurozumi, Sasagu
    Yokoe, Takamichi
    Nozawa, Kazuki
    Ozaki, Yukinori
    Maeda, Tetsuyo
    Yazaki, Shu
    Onishi, Mai
    Fujimoto, Akihiro
    Nakayama, Sayuka
    Tsuboguchi, Yuko
    Iwasa, Tsutomu
    Sakai, Hitomi
    Ogata, Misato
    Terada, Mitsuo
    Nishimura, Meiko
    Onoe, Takuma
    Masuda, Jun
    Kurikawa, Michiko
    Shimokawa, Mototsugu
    Takano, Toshimi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [18] Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results
    Patel, Tejal Amary
    Ensor, Joe
    Rodriguez, Angel Augusto
    Belcheva, Anna
    Darcourt, Jorge German
    Niravath, Polly Ann
    Kuhn, John G.
    Kaklamani, Virginia G.
    Li, Xiaoxian
    Boone, Toniva
    Chang, Jenny Chee Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [19] Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
    Takahiro Nakayama
    Tetsuhiro Yoshinami
    Hiroyuki Yasojima
    Nobuyoshi Kittaka
    Masato Takahashi
    Shoichiro Ohtani
    Seung Jin Kim
    Hiroyuki Kurakami
    Naoko Yamamoto
    Tomomi Yamada
    Takehiko Takata
    Norikazu Masuda
    BMC Cancer, 21
  • [20] Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
    Nakayama, Takahiro
    Yoshinami, Tetsuhiro
    Yasojima, Hiroyuki
    Kittaka, Nobuyoshi
    Takahashi, Masato
    Ohtani, Shoichiro
    Kim, Seung Jin
    Kurakami, Hiroyuki
    Yamamoto, Naoko
    Yamada, Tomomi
    Takata, Takehiko
    Masuda, Norikazu
    BMC CANCER, 2021, 21 (01)
12345